News

REBIF (interferon beta-1a) and AVONEX (interferon beta-1a) are currently used for the treatment of Australians living with relapsing forms of MS. Recently, there were some changes announced to their listing on the PBS.

From 1 April 2023, AVONEX will no longer be available on the Pharmaceutical Benefits Scheme (PBS) for Australians living with MS.

MS Australia is delighted to announce over $3 million of funding towards MS research in 2023. The twenty-two new projects address MS Australia's priorities for MS research, including causes and prevention, better treatments and cures via repair and regeneration of cells.

CEO Rohan Greenland discusses the dramatic escalation in the number of people in Australia living with MS and urges the government to take action so that we can work together to turn the tables on MS.  

A recent study from researchers in Perth has explored the impact of COVID-19 on people living with MS and MS carers, investigating both the highs and lows of the pandemic. A deeper understanding of these experiences can help inform future crises as they unfold, to ensure the best care and health management possible for people living with MS, their carers and loved ones.

International researchers have developed a cutting-edge tool to identify a rare subtype of cell in the brain potentially involved in MS.

Judith Webb was a much-loved primary school teacher, volunteer, wife and mother. Her generosity and courage motivated her husband Bob to allocate a portion of his Will to MS research.

MS Australia has awarded over $3 million in grants for multiple sclerosis (MS) research, providing a major boost in the fight against this increasing and accelerating disease.

The number of Australians living with multiple sclerosis (MS) is increasing at a significant and accelerating rate.

MS Australia congratulates Dr Therese Burke who has been honoured for her significant service to medicine, particularly multiple sclerosis research, and to nursing, by being made a Member of the Order of Australia (AM) in today’s 2023 Australia Day Honours List.

As well as depleting immune cells, new research shows cladribine (Mavenclad) may impede their movement into brain tissue, preventing further damage by multiple sclerosis.

MS Australia CEO Rohan Greenland answers the question, ‘what are the big breakthroughs that lie ahead?’ He details the latest research, treatments and programs that will propel us faster and further along the ‘pathways to cures’.  

Many people living with multiple sclerosis modify their dietary intake after their MS diagnosis, but there is little evidence that dietary modifications influence MS outcomes. A recent Australian study has explored the impact of diet quality specifically on three common MS symptoms; depression, anxiety and fatigue.

The MS Australia Clinical Trials Network is a central point of information for people interested in participating in clinical trials and research studies in MS, or in finding out more details of studies in MS.

MS Plus employee Ben Holgate says he wants to give something back to the charity where he’s worked for the past five years.

MS Australia will be making a submission advocating for the subcutaneous form of Tysabri® to be listed on the PBS, as we welcome affordable access to all treatment options that have been shown in clinical trials to provide safe and effective treatment for MS.

CEO Rohan Greenland reflects on the achievements over the past year and looks ahead to MS Australia’s goals for 2023, where our focus will remain tightly on supercharging MS research, advocacy, education and awareness.

What happens with MS when you stop a disease-modifying therapy, and what is the ideal time window for starting a new one?